Abstract
Modern data on selection and design of poxviruses, which are able to specifically lyse tumor cells of various origins and induce antitumor immunity and apoptosis of malignant cells, are presented in this review. Work is being carried out in several areas, including attenuation of viruses, insertion of immunomodulatory protein genes, and insertion of antitumor protein genes. Thymidine kinase and viral growth factor genes, inactivation of which results in an inability of the virus to replicate in nondividing cells and thus promotes an increase in selectivity for the tumor cells, make the greatest contribution in attenuation of the virus. Among the immunomodulatory proteins, interleukins 2 and 12 and granulocyte-macrophage colony-stimulating factor were the most promising in oncolytic viral therapy. An attempt to use the p53 protein gene, expressed by the Vaccinia virus, for targeted apoptosis of the tumor cells was described. Use of double and triple viral recombinants, which carry genes of differently directed effects, seems very promising. Encouraging results were obtained using the Vaccinia virus in cancer therapy by means of prodrugs and angiogenesis inhibitors. At present, two poxvirus strains are undergoing a third stage of clinical trials as antitumor drugs in the United States.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Addison, C., Bramson, J., Hitt, M., et al., Gene Ther., 1998, vol. 5, pp. 1400–1409.
Biron, C., Semin. Immunol., 1998, vol. 10, pp. 383–390.
Braidwood, L., Dunn, P., Hardy, S., et al., Anticancer Res., 2009, vol. 29, pp. 2159–2166.
Breitbach, C., Reid, T., Burke, J., et al., Cytokine Growth Factor Rev., 2010, vol. 21, pp. 85–89.
Brown, J., Barsoum, J., and Qin, X., J. Interferon Cytokine Res., 2002, vol. 22, pp. 719–728.
Buller, R., Chakrabarti, S., Cooper, J., et al., J. Virol., 1988, vol. 62, pp. 866–874.
Chakrabarti, S., Sisler, J., and Mass, B., BioTechniques, 1997, vol. 23, pp. 1094–1097.
Chalikonda, S., Kivlen, M.H., O’Mallkey, M., et al., Cancer Gene Ther., 2008, vol. 15, pp. 5–25.
Chen, B., Timiryasova, T., Andres, M., et al., Cancer Gene Ther., 2000, vol. 7, pp. 1437–1447.
Chen, B., Timiryasova, T., Haghighat, P., et al., J. Immunother., 2001, vol. 24, pp. 46–57.
Chung, C., Hsiao, J., Chang, Y., and Chang, W., J. Virol., 1998, vol. 72, pp. 1577–1585.
Cox, G., Melillo, G., Chaltopadhyay, U., et al., J. Immunol., 1992, vol. 149, pp. 3290–3296.
Dong, Z., Greene, G., Pettaway, C., et al., Cancer Res., 1999, vol. 59, pp. 872–887.
Ellenhorn, I., Hoshua, D., and Diamond, Don J., Modified Vaccinia Ankara Expressing p53 in Cancer Immunotherapy, US Patent No. 7563448, 2009.
Fenner, F., Henderson, D., Arita, I., et al., Smallpox and Its Eradication, Geneva: WHO, 1988.
Fernandez, N., Levraud, J., Haddada, H., et al., J. Immunol., 1999, vol. 162, pp. 609–617.
Fischer, M., Allen, M., Wilson, W., and Suttle, C., Proc. Natl. Acad. Sci. USA, 2010, vol. 107, no. 45, pp. 19508–19513.
Fodor, I., Timiryasova, T., Denesa, B., et al., J. Urol. (Baltimore), 2005, vol. 173, pp. 604–609.
Fukuda, K. Abei, M., Ugai, H., et al., Cancer Gene Ther., 2009, vol. 16, pp. 126–136.
Garcea, G., Doucas, H., Steward, W., et al., Austr. N. Z. J. Surg., 2006, vol. 76, pp. 830–842.
Goebel, S., Johnson, G., Perkus, M., et al., Virology, 1990, vol. 179, pp. 247–266.
Greco, O. and Dachs, G., J. Cell Physiol., 2001, vol. 187, pp. 22–36.
Gubser, C., Hue, S., Kellam, P., and Smith, G., J. Gen. Virol., 2004, vol. 85, pp. 105–117.
Guse, K., Sloniecka, M., Diaconu, I., et al., J. Virol., 2010, vol. 84, pp. 856–866.
Hainaut, P. and Hollstein, M., Adv. Cancer. Res., 2000, vol. 77, pp. 81–137.
Hanson, D. and Diven, D., Dermatol. Online J., 2003, vol. 9, no. 2, p. 2.37.
Ikeda, N., Adachi, M., Taki, T., et al., Br. J. Cancer, 1999, vol. 79, pp. 1553–1563.
Isayeva, T., Kumar, S., and Ponnazhagan, S., Int. J. Oncol., 2004, vol. 25, pp. 335–343.
Iyer, L., Aravind, L., and Koonin, E., J. Virol., 2001, vol. 75, no. 23, pp. 11720–11734.
Iyer, L., Balaji, S., Koonin, E., and Aravind, L., Virus Res., 2006, vol. 117, pp. 156–184.
Karrasch, M. and Mescheder, A., Use of Oncolytic Viruses and Antiangiogenic Agents in the Treatment of Cancer, US Patent No. 20090317456, 2009.
Kaynor, C., Xin, M., Wakefield, J., et al., J. Interferon Cytokine Res., 2002, vol. 22, pp. 1089–1098.
Kelly, E. and Russell, S., Mol. Ther., 2007, vol. 15, pp. 651–659.
Kim, K., Li, B., Winer, J., et al., Nature, 1993, vol. 362, pp. 841–844.
Kim, J., Oh, Y., Park, B., et al., Mol. Ther., 2006, vol. 14, pp. 361–370.
Kirn, D., Wang, Y., Le Boeuf, F., et al., PLoS Med., 2007, vol. 4, pp. 2001–2010.
Kirn, D., Wang, Y., Liang, W., et al., Cancer Res., 2008, vol. 68, pp. 2071–2075.
Kirn, D. and Thorne, S., Nat. Rev. Cancer, 2009, vol. 9, pp. 64–71.
Kirn, D., Oncolytic Vaccinia Virus Cancer Therapy. US Patent No. 2010/0303714A1, 2010.
Koonin, E. and Yutin, N., Intervirology, 2010, vol. 53, pp. 284–292.
Lee, H. and Essani, K., Open Virol. J., 2010, vol. 4, pp. 1–6.
Lee, J., Hoh, M., Lee, Y., et al., Cancer Gene Ther., 2010, vol. 17, pp. 73–79.
Lee, S., Eisenlohr, L., McCue, P., et al., Cancer Res., 1994, vol. 54, pp. 3325–3328.
Lefkowitz, E., Wang, C., and Upton, C., Virus Res., 2006, vol. 117, pp. 105–118.
Liu, T., Hwang, T., Park, B., et al., Mol. Ther., 2008, vol. 16, pp. 1637–1642.
Liu, J., Wennier, S., and McFadden, G., Microb. Infect., 2010, vol. 12, pp. 1144–1152.
Malarme, D., Cordier, Y., and Sene, C., Process for Producing Poxviruses and Poxvirus Compositions, US Patent No. 2010/0008953A1, 2010.
McCart, A., Puhlmann, M., Lee, J., et al., Gene Ther., 2000, vol. 7, pp. 1217–1223.
McCart, A., Ward, J., Lee, J., et al., Cancer Res., 2001, vol. 61, pp. 8751–8757.
McCart, A., Bartlett, D., and Moss, B., Combined Growth Factor-Deleted and Thymidine Kinase-Deleted Vaccinia Vinus Vector, US Patent No. 7208313, 2007.
McLysaght, A., Baldi, P., and Gaut, B., Proc. Natl. Acad. Sci. USA, 2003, vol. 100, pp. 15655–15660.
Meerani, S. and Yao, Y., Eur. J. Sci. Res., 2010, vol. 40, pp. 156–171.
Mercer, J. and Helenius, A., Science, 2008, vol. 320, pp. 531–535.
Moss, B., Ahn, B., Amegadzie, B., et al., J. Biol. Chem., 1991, vol. 266, no. 3, pp. 1355–1358.
Mass, B., Virology, 2006, vol. 344, pp. 48–54.
Mass, B. and Damon, I., Poxviridae, in Fields Virology, 5 ed., Knipe, D.M. and Howley, P.M., Eds., Philadelphia, 2007.
Paoletti, E. and Panicali, D., Modified Vaccinia Virus and Methods for Making and Using the Same, US Patent No. 4769330, 1988.
Robinson, B., Mukherjee, S., Davidson, A., et al., J. Immunother., 1998, vol. 21, pp. 211–217.
Ryu, H., Chang, K., Chang, S., et al., Int. J. Gynecol. Cancer, 2000, vol. 10, pp. 417–424.
Scappaticci, F., Contreras, A., Smith, R., et al., Angiogenes, 2001, vol. 4, pp. 263–268.
Shchelkunov, S., Marennikova, S., and Moyer, R., Orthopoxviruses Pathogenic for Humans, Berlin, 2005.
Schriewer, J., Buller R., Owens G, Meth. Mol. Biol., 2004, vol. 269, pp. 289–308.
Sheridan, J., Marsters, S., Pitti, R., et al., Science, 1997, vol. 277, p. 818.
Seubert, C., Striltzker, J., Hess, M., et al., Cancer. Gene Ther., 2011, vol. 18, pp. 42–52.
Smee, D. and Sidwell, R., Antiviral Res., 2003, vol. 57, pp. 41–52.
Smith, G. and Moss, B., Gene, 1983, vol. 25, pp. 21–28.
Thorne, S., Hwang, T., O’Gorman, W., et al., J. Clin. Invest., 2007, vol. 117, pp. 3350–3358.
Timiryasova, T., Li, J., Chen, B., et al., Oncol. Res., 1999, vol. 11, pp. 133–144.
Tysome, J., Briat, A., Alusi, G., et al., Gene Ther., 2009, vol. 16, pp. 1223–1233.
Wein, L., Wu, J., and Kirn, D., Cancer Res., 2003, vol. 63, pp. 1317–1324.
Wiley, S., Schooley, K., Smolak, P., et al., Immunity, 1995, vol. 3, pp. 673–682.
Wong, H., Lemoine, N., and Wang, Y., Viruses, 2010, vol. 2, pp. 78–106.
Zeh, H. and Bartlett, D., Cancer Gene Ther., 2002, vol. 9, pp. 1001–1012.
Zhang, Q., Yu, Y., Wang, E., et al., Cancer Res., 2007, vol. 67, pp. 10038–10046.
Zhang, Q., Liang, C., Yu, Y., et al., Mol. Genet. Genom., 2009, vol. 282, pp. 417–435.
Ziauddin, M., Guo, Z., O’Malley, M., et al., Gene Ther., 2010, vol. 17, pp. 550–559.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © G.V. Kochneva, G.F. Sivolobova, K.V. Yudina, I.V. Babkin, P.M. Chumakov, S.V. Netesov, 2012, published in Molekulyarnaya Genetika, Mikrobiologiya i Virusologiya, 2012, No. 1, pp. 8–15.
About this article
Cite this article
Kochneva, G.V., Sivolobova, G.F., Yudina, K.V. et al. Oncolytic poxviruses. Mol. Genet. Microbiol. Virol. 27, 7–15 (2012). https://doi.org/10.3103/S0891416812010041
Received:
Published:
Issue Date:
DOI: https://doi.org/10.3103/S0891416812010041